0001562180-22-007011.txt : 20221004
0001562180-22-007011.hdr.sgml : 20221004
20221004174907
ACCESSION NUMBER: 0001562180-22-007011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220930
FILED AS OF DATE: 20221004
DATE AS OF CHANGE: 20221004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Katkin Keith
CENTRAL INDEX KEY: 0001314596
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37708
FILM NUMBER: 221293416
MAIL ADDRESS:
STREET 1: C/O UROVANT SCIENCES, INC.
STREET 2: 5281 CALIFORNIA AVENUE, SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92617
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001395937
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320162505
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-419-1400
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-09-30
false
0001395937
Syndax Pharmaceuticals Inc
SNDX
0001314596
Katkin Keith
C/O SYNDAX PHARMACEUTICALS, INC.
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3
WALTHAM
MA
02451
true
false
false
false
Common Stock
2022-09-30
4
M
false
2914.00
7.88
A
34914.00
D
Common Stock
2022-09-30
4
S
false
2914.00
25.0707
D
32000.00
D
Common Stock
2022-09-30
4
M
false
647.00
8.93
A
32647.00
D
Common Stock
2022-09-30
4
S
false
647.00
25.0707
D
32000.00
D
Common Stock
2022-10-03
4
M
false
167.00
7.88
A
32167.00
D
Common Stock
2022-10-03
4
S
false
167.00
25.00
D
32000.00
D
Common Stock
2022-10-03
4
M
false
13.00
8.93
A
32013.00
D
Common Stock
2022-10-03
4
S
false
13.00
25.00
D
32000.00
D
Common Stock
2022-10-04
4
M
false
137.00
7.88
A
32137.00
D
Common Stock
2022-10-04
4
S
false
137.00
25.00
D
32000.00
D
Common Stock
2022-10-04
4
M
false
223.00
8.93
A
32223.00
D
Common Stock
2022-10-04
4
S
false
223.00
25.00
D
32000.00
D
Stock Options (Right to buy)
8.93
2022-09-30
4
M
false
647.00
0.00
D
2028-05-23
Common Stock
647.00
0.00
D
Stock Options (Right to buy)
7.88
2022-09-30
4
M
false
2914.00
0.00
D
2029-06-10
Common Stock
2914.00
0.00
D
Stock Options (Right to buy)
8.93
2022-10-03
4
M
false
13.00
0.00
D
2028-05-23
Common Stock
13.00
0.00
D
Stock Options (Right to buy)
7.88
2022-10-03
4
M
false
167.00
0.00
D
2029-06-10
Common Stock
167.00
0.00
D
Stock Options (Right to buy)
8.93
2022-10-04
4
M
false
223.00
0.00
D
2028-05-23
Common Stock
223.00
0.00
D
Stock Options (Right to buy)
7.88
2022-10-04
4
M
false
137.00
0.00
D
2029-06-10
Common Stock
137.00
0.00
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
The sale prices ranged from $25.00 to $25.215.
The sale price was $25.00.
This option is fully vested.
/s/ Michael A. Metzger, as Attorney-in-Fact
2022-10-04